Table 5. Patient characteristics.
| Characteristics | Number of patients (%) (Sample size = 57) |
|---|---|
| Histology | |
| Ductal | 42 (73,7%) |
| Lobular | 6 (10,5%) |
| Other | 0 (0%) |
| Unknown | 9 (15,8%) |
| Histological grade of the primary tumour | |
| 1–2 | 28 (49,1%) |
| 3 | 24 (42,1%) |
| Unknown | 5 (8,8%) |
| Stage at the initial diagnosis | |
| I | 7 (12,3%) |
| II | 22 (38,6%) |
| III | 10 (17,5%) |
| IV | 18 (31,6%) |
| Phenotype | |
| HER2 | 9 (15,8%) |
| Triple negative | 7 (12,3%) |
| Luminal | 41 (71,9%) |
| Disease free interval | |
| 0 (de novo MBC) | 18 (31,6%) |
| <2 years | 5 (8,8%) |
| >2 years | 34 (59,6%) |
| Median No of metastatic disease sites (1st– 3rd quartile) | 7 (3–19) |
| Disease site | |
| CNS | 0 (0%) |
| Lung | 12 (21%) |
| Liver Bone |
9 (15,8%) |
| 43 (75,4%) | |
| Lymph nodes | 38 (66,7%) |
| Other | 5 (8,8%) |
CNS = Central Nervous System; HER-2 = Human Epidermal Growth Factor Receptor-2; MBC = Metastatic breast Cancer